30 closest matches · ranked by relevance
Platinum Sensitive Recurrent High-grade Serous Ovarian Cancer With Mutated p53
Primary: Phase Ib: Dose-limiting Toxicities (DLT) (See Description) of Combined APR-246 and Carboplatin/PLD Regimen — 0; 1; 0 Participants
High-grade Serous Ovarian Cancer
Primary: Overall Response Rate (ORR) — 1; 0; 0; 0 Participants
Primary Peritoneal Carcinoma · Ovarian Carcinoma · Fallopian Tube Carcinoma
Primary: Percentage of Patients That Achieve Maximal Surgical Debulking — 10 Participants
Ovarian Cancer · Fallopian Tube Cancer · Peritoneal Neoplasms
Primary: Progression-Free Survival (PFS) Assessed by Investigator as Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) - Intent-to-Treat (ITT) Population…
Endometrial Cancer
Primary: Overall Survival at 2 Years and 5 Years — 93; 85 percentage of participants
Ovarian Cancer
Primary: PFS — 29.8 Months
Endometrial Cancer
Primary: Progression Free Survival Differences Between Treatment Arms. — 8.049; 12.945 months
Ovarian Cancer · Fallopian Tube Cancer · Primary Peritoneal Carcinoma
Primary: Progression-free Survival — 8.85; 8.32 months
Ovarian Cancer
Primary: Objective Tumor Response — 12.5; 12.1 percentage of participants
Non-Germline BRCA Mutated Ovarian Cancer
Primary: Progression Free Survival (PFS) — 9.2 months
High-grade Serous Ovarian Carcinoma · Ovarian Carcinoma
Primary: Change From Baseline in Circulating Tumor Deoxyribonucleic Acid (ctDNA) — 0.08; 0.04 Fold change
Relapsed Ovarian Cancer, BRCA Mutation, Platinum Sensitivity
Primary: Objective Response Rate, Defined as the Percentage of Subjects With a Best Overall Response of Confirmed Complete Response (CR) or Partial Response (PR) — 69.3; 64.0…
Genital Neoplasms, Female · Fallopian Tube Neoplasms · Ovarian Neoplasms
Primary: Progression Free Survival (PFS) — 20.0; 22.2 Months — p=0.199
Carcinosarcoma, Ovarian
Primary: Proportion of Patients With Completion of 4 Cycles of CT + GB — 0.7826 proportion of patients
Ovarian Cancer
Primary: Progression Free Survival (PFS) of Combination Platinum Based Therapy With Anti-Programmed Death (PD)-1 Therapy Followed by Maintenance Anti-PD-1 Therapy in Patients…
Ovarian Cancer
Primary: Overall Response Rate (ORR) — 0; 0 participants
Ovarian Cancer
Primary: Progression Free Survival (PFS) (According to Response Evaluation Criteria in Solid Tumours [RECIST]) — 8.4; 4.8 Months — p=<0.00001
Fallopian Tube Cancer · Ovarian Cancer · Peritoneal Cavity Cancer
Primary: Number of Patients With Treatment-emergent Adverse Events — 12; 6; 6; 12 Participants
Borderline Ovarian Serous Tumor · Low Grade Ovarian Serous Adenocarcinoma · Micropapillary Serous Carcinoma
Primary: Tumor Response — 15.4 percentage of patients
Ovarian Cancer
Primary: Best Overall Tumor Response — 6; 25; 10; 5 participants
Ovarian Cancer · Fallopian Tube Cancer · Primary Peritoneal Cancer
Primary: Consolidation Progression-Free Survival — 13.3; 18.9 months
Ovarian Neoplasm · Fallopian Tube Cancer · Primary Peritoneal Cancer
Primary: Clinical Response Rate. — 0; 19; 21; 60 percentage of participants
Ovarian, Fallopian Tube, Peritoneal Cancer, P53 Mutation
Primary: Objective Response Rate (ORR) — 1; 11; 7; 8 Participants
Fallopian Tube Cancer · Ovarian Cancer · Peritoneal Cavity Cancer
Primary: Overall Survival — 32 months
Epithelial Ovarian Cancer · Primary Peritoneal Cancer · Fallopian Tube Cancer
Primary: Number of Protocol Defined Adverse Events in Patients Receiving Neoadjuvant Carboplatin, Paclitaxel, and Bevacizumab — 7 protocol defined adverse events
Ovarian Cancer · Fallopian Tube Cancer · Peritoneal Neoplasms
Primary: Progression-Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by the Investigator in Participants With Programmed…
Ovarian Cancer
Primary: 2-year Progression-free Survival — 40; 40 percentage of participants
Platinum-sensitive Ovarian Cancer, Second-line, Third-line, or Fourth-line
Primary: Number of Participants With Drug-related Adverse Events (AEs) of Grade 3 or Higher — 20 Participants
Neoplasms, Ovarian
Primary: Objective Response Rate (ORR) by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 Per Investigator Assessment — 20.0; 13.9 Percent of participants
Recurrent Fallopian Tube Carcinoma · Recurrent Ovarian Carcinoma · Recurrent Primary Peritoneal Carcinoma
Primary: Four Cycle Progression-free Survival Rate — 8 Participants